Three-dimensional quantitative structure activity relationship computational approaches for prediction of human in vitro intrinsic clearance.
暂无分享,去创建一个
[1] S. Ekins,et al. Three and four dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. , 1999, Pharmacogenetics.
[2] G. Granneman,et al. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.
[3] D. Greenblatt,et al. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. , 1996, Journal of clinical psychopharmacology.
[4] I Skånberg,et al. In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. , 2009, Acta pharmacologica et toxicologica.
[5] C. Waller,et al. Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[6] S. Ekins,et al. Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[7] R. Obach,et al. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[8] B. Hoener,et al. Predicting the hepatic clearance of xenobiotics in humans from in vitro data , 1994, Biopharmaceutics & drug disposition.
[9] S. Ekins,et al. Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6. , 1999, The Journal of pharmacology and experimental therapeutics.
[10] S. Ekins,et al. Quantitative differences in phase I and II metabolism between rat precision-cut liver slices and isolated hepatocytes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[11] T Lavé,et al. Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. , 1999, Journal of medicinal chemistry.
[12] J. Houston,et al. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. , 1999, British journal of clinical pharmacology.
[13] J B Houston,et al. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.
[14] B. Ring,et al. The Use of In Vitro Metabolism Techniques in the Planning and Interpretation of Drug Safety Studies , 1995, Toxicologic pathology.
[15] M. Eichelbaum,et al. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. , 1992, The Journal of pharmacology and experimental therapeutics.
[16] S. Ekins,et al. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.
[17] S. Ekins,et al. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. , 1999, The Journal of pharmacology and experimental therapeutics.
[18] M. Bayliss,et al. Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes. , 1990, Biochemical Society transactions.
[19] T Ishizaki,et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. , 1997, Pharmacology & therapeutics.
[20] D J Rance,et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.
[21] B. Ring,et al. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. , 1993, Drug metabolism reviews.
[22] A. Vickers,et al. The biotransformation of the ergot derivative CQA 206-291 in human, dog, and rat liver slice cultures and prediction of in vivo plasma clearance. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[23] T Iwatsubo,et al. PREDICTION OF IN VIVO DRUG DISPOSITION FROM IN VITRO DATA BASED ON PHYSIOLOGICAL PHARMACOKINETICS , 1996, Biopharmaceutics & drug disposition.
[24] S. Ekins. Past, present, and future applications of precision-cut liver slices for in vitro xenobiotic metabolism. , 1996, Drug metabolism reviews.
[25] J. Houston,et al. Kinetics of drug metabolism in rat liver slices. Rates of oxidation of ethoxycoumarin and tolbutamide, examples of high- and low-clearance compounds. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[26] J. Magdalou,et al. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. , 1999, The Journal of pharmacology and experimental therapeutics.